Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial.
Depalma
Ralph G
RG
Department of Veterans Affairs, Washington, DC, USA. ralph.depalma@va.gov
Hayes
Virginia W
VW
Chow
Bruce K
BK
Shamayeva
Galina
G
May
Patricia E
PE
Zacharski
Leo R
LR
D000368:Aged; D000369:Aged, 80 and over; D050197:Atherosclerosis / Q000097:blood* / Q000401:mortality* / Q000628:therapy; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D005293:Ferritins / Q000097:blood*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D018836:Inflammation Mediators / Q000097:blood*; D016753:Interleukin-10 / Q000097:blood; D007376:Interleukin-2 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007501:Iron / Q000097:blood*; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000097:blood* / Q000401:mortality* / Q000628:therapy; D018962:Phlebotomy; D016016:Proportional Hazards Models; D011446:Prospective Studies; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000097:blood; D018570:Risk Assessment; D012307:Risk Factors; D016037:Single-Blind Method; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C508609:IL10 protein, human; C508594:IL2 protein, human; C508600:IL6 protein, human; D018836:Inflammation Mediators; D007376:Interleukin-2; D015850:Interleukin-6; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D002097:C-Reactive Protein; D005293:Ferritins; D007501:Iron